The integrated pharmacometrics approach presented in this study helps with optimal benefit–risk assessments for the use of SAF-189s in the treatment of patients with ALK+/ROS1+ advanced NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.